News & Events: ASCENION GmbH - A LifeScience company

Cookie Preference

This website uses cookies to improve user experience. Please select an option. Privacy Policy

About us
- Profile
- Team
  - Berlin
  - Brunswick
  - Hamburg
  - Hanover
  - Munich
- Advisory Board
- LifeScience Foundation
- Careers
Partners
- Science
- Industry
- Knowledge and technology transfer
Services
- For Institutions, Inventors and Founders
  - Protect your idea
  - Develop your project
  - Commercialize your research
  - Start your company
  - Training and advanced services
- For industry and investors
  - Identify your commercial opportunity
  - Innovation consultancy
- BioVaria
Technology Offers
- Therapeutics & Diagnostics
- Research Materials,
  Tools & Analytics
- Medical Devices,
  Software & Equipment
- Green & White
  Biotech
Start-ups
- Start-up coaching
- Startup Pitch & Partner
- Equity portfolio
Impact
- Figures and Annual Reviews
- Case studies
- Initiatives
News & Events
- Webinars
Contact

News

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions

Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.

16 partners from academia and industry will closely collaborate to prepare a future generation of scientists with outstanding skills in both machine learning and chemistry, to create new AI methods for drug research.

Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.

This year’s BioVaria is digital and takes place exclusively online from the 26 to 28 April 2021.

In December 2020 the Ascenion team gained two new colleagues: Dr Sören Rindfleisch in Hanover and Hubert Ludwiczak in München.

As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.

We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive…

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

Ascenion’s portfolio company Cardior Pharmaceuticals announced positive results of a Phase Ib study with its first-in-class compound CDR132L.

Ascenion welcomes a new colleague to the Munich office: Stefanie Danzer joined in October 2020 to support the back office in event management and corporate communications.

Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.

Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.

How is the German start-up sector doing? Are there ‘zombies’ here too – as in the USA? And what should we be looking out for? A number of heads of German technology transfer organisations were interviewed for this overview, including Ascenion’s Christian Stein.